PharmAust CEO's sayanora triggers stock plunge
Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ABA | Ann: SHINTR: ABA: D&O Disclosure Notices | 22/12/20 | 0 | 326 | |||
|
|||||||
ABA | Ann: TRANSACT: ABA: Abano Scheme Unconditional at $5.20 per share | 22/12/20 | 0 | 407 | |||
|
|||||||
ABA | Ann: TRANSACT: ABA: Shareholder Letter | 10/12/20 | 0 | 470 | |||
|
|||||||
ABA | Ann: TRANSACT: ABA: Abano Scheme Receives Final Court Approval | 09/12/20 | 0 | 286 | |||
|
|||||||
ABA | Ann: MEMO: ABA: Abano Healthcare Group Limited ("ABA") -Intention to delist | 08/12/20 | 0 | 350 | |||
|
|||||||
ABA | Ann: TRANSACT: ABA: Abano Shareholders Vote in Favour of Scheme | 25/11/20 | 0 | 366 | |||
|
|||||||
ABA | Ann: TRANSACT: ABA: Abano Special Meeting Speech and Presentation | 25/11/20 | 0 | 337 | |||
|
|||||||
ABA | Ann: GENERAL: ABA: South Australia COVID lockdown; No impact on Scheme | 19/11/20 | 0 | 316 | |||
|
See All Discussions